RHYTHM PHARMACEUTICALS, INC. Logo

RHYTHM PHARMACEUTICALS, INC.

Develops precision medicines for rare genetic diseases causing severe obesity and hyperphagia.

RYTM | US

Overview

Corporate Details

ISIN(s):
US76243J1051
LEI:
Country:
United States of America
Address:
222 BERKELEY STREET, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing precision medicines for rare neuroendocrine diseases. The company focuses on treating conditions characterized by hyperphagia (insatiable hunger) and severe obesity that stem from rare genetic deficiencies. Its lead therapeutic, setmelanotide (marketed as IMCIVREE), is a precision medicine designed to address the root cause of these disorders by targeting the melanocortin-4 receptor (MC4R) pathway. Rhythm is advancing a portfolio of treatment options to transform the lives of patients and families affected by these debilitating conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:05
Regulatory News Service
8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
English 126.1 KB

Automate Your Workflow. Get a real-time feed of all RHYTHM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for RHYTHM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for RHYTHM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tyra Biosciences, Inc. Logo
Biotech developing precision FGFR medicines for cancer and genetic disorders.
United States of America
TYRA
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY
UNION KOREA PHARM CO.,Ltd Logo
Develops and manufactures prescription drugs like antibiotics and analgesics for global markets.
South Korea
080720
uniQure N.V. Logo
Developing AAV-based gene therapies for rare liver and central nervous system disorders.
United States of America
QURE
UNITED THERAPEUTICS Corp Logo
Develops therapies for chronic diseases and manufactures organs for transplantation.
United States of America
UTHR
Universe Pharmaceuticals INC Logo
Manufactures, markets, and distributes TCM derivative products and biomedical drugs.
United States of America
UPC
Univo Pharmaceuticals Ltd. Logo
Vertically integrated biopharma firm developing medical cannabis treatments with a focus on CNS.
Israel
UNVO-M

Talk to a Data Expert

Have a question? We'll get back to you promptly.